DEFA14A: Seres Therapeutics to Sell VOWST to Nestle, Enhancing Cash Runway and Retiring Debt

Seres Therapeutics has signed an asset purchase agreement with Nestle for VOWST, aimed at bolstering its financial position and continuing its focus on developing therapies for life-threatening infections.

Summary

• Seres Therapeutics has entered into an asset purchase agreement with Nestle for VOWST, a life-changing therapy.
• The deal is expected to close by early to mid-fall.
• The agreement will significantly enhance Seres' cash runway and allow the company to retire its debt with Oaktree Capital Management.
• Seres will provide transition services for VOWST through the first quarter of 2025 and manufacturing support through the end of 2025.
• The contract with Bacthera will be terminated at closing.
• Following the SER-155 readout at the end of September, Seres will refine its strategic long-term plan.
• A special meeting of Seres stockholders will be held to obtain approval for the proposed transaction.
• The company plans to host opportunities for employees to connect and learn more about SER-155.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strategic sale of VOWST, which strengthens the company's financial position and allows it to focus on its pipeline. However, there are risks associated with the transaction and potential job losses, which temper the overall sentiment.

Positives

• The asset purchase agreement with Nestle enhances Seres' cash runway.
• The deal allows Seres to retire its debt with Oaktree Capital Management.
• The agreement supports ongoing VOWST availability through transition and manufacturing support.
• The company can focus on progressing SER-155 following the Phase 1B study readout.

Negatives

• Termination of the contract with Bacthera.
• Some PDQS employees may receive offers of employment from Nestle, indicating potential job losses at Seres.

Risks

• The transaction is subject to stockholder approval and other closing conditions.
• Failure to receive conditional portions of the Transaction Consideration, including the Installment Payments and the Milestone Payments.
• The transaction could disrupt management's attention from ongoing business operations.
• There is uncertainty regarding Seres' 50% share of the net profit/net loss during the profit sharing period from the Closing date until December 31, 2025.
• Potential litigation related to the proposed transaction.

Future Outlook

Seres plans to refine its strategic long-term plan after the SER-155 readout and continue to support SER-155 and beyond in its mission to transform patient lives.

Management Comments

• Eric D. Shaff, President and CEO, stated he is pleased to share that they have signed the asset purchase agreement with Nestle.
• Eric D. Shaff stated he is extremely proud of the life-changing therapy they have built together with VOWST.
• Eric D. Shaff stated he is incredibly optimistic and energized about their future.

Industry Context

This announcement reflects a strategic shift for Seres, focusing on its pipeline while divesting a key asset to a larger player in the nutrition and health space, Nestle. This is not uncommon in the biotech industry, where companies often prioritize specific therapeutic areas or development programs.

Comparison to Industry Standards

• Divesting assets to larger companies is a common strategy in the pharmaceutical industry to focus on core competencies and pipeline development.
• For example, similar to how Roche acquired Genentech to expand its oncology portfolio, Nestle's acquisition of VOWST allows them to diversify into microbiome therapeutics.
• The financial terms of the deal will need to be compared to other similar asset sales in the microbiome or gastroenterology space to assess its value.

Stakeholder Impact

• Shareholders will vote on the proposed transaction.
• Some employees may receive offers of employment from Nestle.
• Patients will continue to have access to VOWST through transition and manufacturing support.
• The company will focus on progressing SER-155, potentially benefiting future patients.

Next Steps

• Obtain stockholder approval for the proposed transaction.
• Close the deal with Nestle by early to mid-fall.
• Refine the strategic long-term plan after the SER-155 readout.
• Host opportunities for employees to connect and learn more about SER-155.

Key Dates

Keywords

Seres Therapeutics, Nestle, VOWST, Asset Purchase Agreement, SER-155, Debt Retirement, Cash Runway, Transaction, Stockholder Approval, Pharmaceuticals